These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26019183)

  • 1. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
    Clin Chem; 2015 Jun; 61(6):850-69. PubMed ID: 26019183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney GR; Huestis MA
    Clin Chem; 2016 Feb; 62(2):367-77. PubMed ID: 26823611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.
    Newmeyer MN; Swortwood MJ; Barnes AJ; Abulseoud OA; Scheidweiler KB; Huestis MA
    Clin Chem; 2016 Dec; 62(12):1579-1592. PubMed ID: 27899456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ
    Newmeyer MN; Swortwood MJ; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
    Clin Chem; 2017 Mar; 63(3):647-662. PubMed ID: 28188235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis effects on driving lateral control with and without alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Pierce RS; Gorelick DA; Gaffney G; Huestis MA
    Drug Alcohol Depend; 2015 Sep; 154():25-37. PubMed ID: 26144593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):690-701. PubMed ID: 26257143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
    Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
    Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.
    Swortwood MJ; Newmeyer MN; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
    Drug Test Anal; 2017 Jun; 9(6):905-915. PubMed ID: 27647820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.
    Lee D; Bergamaschi MM; Milman G; Barnes AJ; Queiroz RH; Vandrey R; Huestis MA
    J Anal Toxicol; 2015 Oct; 39(8):580-7. PubMed ID: 26378131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
    Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.
    Marsot A; Audebert C; Attolini L; Lacarelle B; Micallef J; Blin O
    J Pharm Pharm Sci; 2016; 19(3):411-422. PubMed ID: 27806250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
    Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
    J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis effects on driving longitudinal control with and without alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Pierce RS; Gorelick DA; Gaffney G; Huestis MA
    J Appl Toxicol; 2016 Nov; 36(11):1418-29. PubMed ID: 26889769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
    Karschner EL; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
    Drug Alcohol Depend; 2012 Oct; 125(3):313-9. PubMed ID: 22464363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
    Schwope DM; Karschner EL; Gorelick DA; Huestis MA
    Clin Chem; 2011 Oct; 57(10):1406-14. PubMed ID: 21836075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
    Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
    Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
    Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
    Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.
    Vandrey R; Herrmann ES; Mitchell JM; Bigelow GE; Flegel R; LoDico C; Cone EJ
    J Anal Toxicol; 2017 Mar; 41(2):83-99. PubMed ID: 28158482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.